XPro1595 (XPro™)
Alzheimer's Disease (with brain inflammation)
Phase 2Active
Key Facts
About INmune Bio
INmune Bio is pioneering a precision approach to innate immune system modulation, focusing on restoring normal function rather than broad suppression. The company has two late-stage assets with near-term regulatory and pivotal-trial milestones, targeting significant markets in Alzheimer's disease and oncology. Its clinical development strategy emphasizes matching drug mechanism to patient biology and using relevant outcome metrics that prioritize patient benefit.
View full company profile